){kind=logo}
){kind=logo}
){kind=logo}
Qilu Pharmaceutical
“We look forward to connecting with global partners at BIO Partnering for Oncology in Chicago during ASCO week. As one of the top three pharmaceutical companies in China, Qilu Pharmaceutical has built a robust pipeline with over 30 innovative oncology programs spanning IND-stage through Phase III clinical development. Our platforms include next-generation multi-specific antibodies and T-cell engagers, proprietary ADC technologies, innovative small molecules including inhibitors, PROTACs, and molecular glues, and emerging cell therapies. We are actively exploring global partnerships and out-licensing opportunities to accelerate the delivery of transformative therapies to patients worldwide.”
Shawn Xu, PhD, EMBA
VP, Business Development & Licensing
Head of Boston Innovation Center, Qilu Pharmaceutical
VCU Massey Comprehensive Cancer Center
“VCU Massey Comprehensive Cancer Center is seeking a partner for PEPD-G278D, a first-in-class protein that eliminates EGFR and HER2 at the source. It achieved 100% complete responses in Enhertu-resistant PDX models with no off-target toxicity. With a successful Pre-IND meeting completed, the program is now seeking a strategic partner to advance toward IND and first-in-human trials.”
Dr. Arup Bhattacharya, PhD
Research Scientist
Office of Clinical Transformation, Dept of Pharmacology & Toxicology
Massey Comprehensive Cancer Center
Blood Cancer United
“Blood Cancer United’s Therapy Acceleration Program (TAP) works hand in hand with the biotech community with a shared urgency to transform outcomes in blood cancers. At BIO Partnering for Oncology, our partnering goal is to work with biotech innovators committed to advancing novel therapies to patients with greater speed and impact. Through strategic investment and partnership, TAP helps reduce development risk, accelerate progress, and deliver meaningful advances for the blood cancer community.”
Blaine Robinson, PhD
Vice President, Therapy Acceleration Program
Blood Cancer United
The University of Chicago
“The University of Chicago has a world class research and medical center, including an NCI designated cancer center. We have many researchers sharing their translational work and are interested in engaging partners at BIO Partnering for Oncology who are looking to expand their biotech IP portfolio. We also hope to build and grow clinical research collaborations, including meeting with service providers for our incubator space, as well as connecting with investors interested in early access to startups.”
Mike Hinton
Senior Manager, Business Development & Technology Marketing
The University of Chicago
Bantam Pharmaceutical
"Bantam is a clinical stage oncology company with an ongoing phase 1 study enrolling patients with solid tumors or lymphomas. We expect significant value creation milestones to emerge over the next 3-6 months and are currently raising a round of capital to expand our phase 1 study in preparation for phase 2 in 2027. Our small molecule is administered orally and features a novel mechanism of action that selectively kills aggressive tumor cells, independent of genomic alterations (such as those in k-ras, c-myc, TP53 and others) by modulating a well-characterized mitochondrial pathway. Our goal is to identify a biopharma partner with whom we can execute a transaction to rapidly develop, globally register and commercialize this exciting first-in-class therapeutic."
Michael Stocum
Chief Executive Officer
Bantam Pharmaceutical
SeaX Ventures
"At SeaX Ventures, our primary goal for at BIO Partnering for Oncology is to connect with visionary oncology biotech companies ready to leverage our SEA Health Innovation Hub (SEA HI Hub) and 'Time Machine' Thesis. We connect breakthrough innovation with Southeast Asia's clinical ecosystem, helping founders lower clinical trial costs and accelerate patient recruitment by 5x while maintaining US FDA standards. Furthermore, through our deeptech fund SeaX Ventures, we offer the unique advantage of potential follow-on funding from our Fund III for companies that demonstrate favorable clinical outcomes."
Kid Parchariyanon
Managing Partner
SeaX Ventures
Kaida BioPharma
"During BIO Partnering for Oncology, our goal at Kaida Biopharma is simple: build the right partnerships that move new options forward for women with ovarian cancer. Kaida is advancing therapies designed to address the biological drivers of these tumors and the gaps that remain for patients with limited treatment choices. We are looking for partners who share the urgency to translate promising science into real progress for ovarian cancer patients."
Dr. Stella K. Vnook
Co-Founder and Chairperson of the Board of Directors
Mark Booth
Chief Commercial Officer (CCO)
Kaida BioPharma
PTM Therapeutics
"I am excited to be attending BIO Partnering for Oncology and share more about PTM Therapeutics. We are a preclinical stage company finding potential therapeutic targets created by the diversity of post-translational modifications (PTM). Epigenetic regulation of specific PTMs have been shown to correlate with disease progression, including inflammation and cancer. We have a lead program targeting solid tumors, including metastatic colon cancer. We are actively seeking funding to support IND-enabling activities and are also open to partnership/collaboration opportunities."
Jennifer C. Cheng, Ph.D., JD
CEO/Co-Founder
PTM Therapeutics
Kalekona Radiotheranostics
Kalekona Radiotheranostics is advancing a targeted pipeline of radiotheranostic peptides against high-value, underserved oncology indications — including glioblastoma and pancreatic cancer — where current standards of care have failed patients. Radiotheranostics is one of the fastest-growing modalities in oncology, and we are building at the forefront of that wave. At BIO Partnering for Oncology, we are looking to partner with investors and biotech organizations who recognize this inflection point and have the capital, infrastructure, and therapeutic development expertise to help us scale.
)